Search tips
Search criteria 


Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
BMC Cancer. 2012; 12: 95.
Published online Mar 20, 2012. doi:  10.1186/1471-2407-12-95
PMCID: PMC3364915
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Gargi Ghosh,1,3 Xiaojun Lian,1 Stephen J Kron,2 and Sean P Palecekcorresponding author1
1Department of Chemical and Biological Engineering, University of Wisconsin, Madison, 1415 Engineering Drive, Madison, WI 53706, USA
2Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA
3Department of Mechanical Engineering, University of Michigan, Dearborn, MI 48128, USA
corresponding authorCorresponding author.
Gargi Ghosh: gargi/at/; Xiaojun Lian: lian/at/; Stephen J Kron: skron/at/; Sean P Palecek: palecek/at/
Received August 3, 2011; Accepted March 20, 2012.
Epidermal growth factor receptor (EGFR) signaling plays an important role in non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been effective in treating a subset of patients bearing somatic EFGR mutations. However, the cancer eventually progresses during treatment with EGFR inhibitors, even in the patients who respond to these drugs initially. Recent studies have identified that the acquisition of resistance in approximately 50% of cases is due to generation of a secondary mutation (T790M) in the EGFR kinase domain. In about 20% of the cases, resistance is associated with the amplification of MET kinase. In the remaining 30-40% of the cases, the mechanism underpinning the therapeutic resistance is unknown.
An erlotinib resistant subline (H1650-ER1) was generated upon continuous exposure of NSCLC cell line NCI-H1650 to erlotinib. Cancer stem cell like traits including expression of stem cell markers, enhanced ability to self-renew and differentiate, and increased tumorigenicity in vitro were assessed in erlotinib resistant H1650-ER1 cells.
The erlotinib resistant subline contained a population of cells with properties similar to cancer stem cells. These cells were found to be less sensitive towards erlotinib treatment as measured by cell proliferation and generation of tumor spheres in the presence of erlotinib.
Our findings suggest that in cases of NSCLC accompanied by mutant EGFR, treatment targeting inhibition of EGFR kinase activity in differentiated cancer cells may generate a population of cancer cells with stem cell properties.
Keywords: EGFR tyrosine kinase, Erlotinib, Cancer stem cells, Tumor spheroids, Side population
Articles from BMC Cancer are provided here courtesy of
BioMed Central